文献速递妇科

绝经期现代管理:我们测量的指标是否重要?

Modern Management of the Menopause: Are We Measuring What Matters?
PubMed 文献 · BJOG · 2026-02-08

本文通过方法学综述评估绝经核心结局指标集(COMMA COS)在随机对照试验中的采用情况。结果显示结局报告与COS的一致性中等,症状困扰类结局报告从历史2%升至注册试验62%,但MHT和阴道雌激素未全面评估所有核心结局,治疗满意度和排尿困难仅9%研究报告。

要点

  • COMMA COS采用率有限,虽症状体验类结局报告增加
  • 历史试验仅2%报告症状困扰,注册试验升至62%
  • MHT和阴道雌激素未按全部核心结局评估,满意度仅9%

核心结论

  • 尽管COMMA COS获强力支持且症状体验与影响报告改善,但完整COS采用仍有限,呼吁优先报告反映患者生活体验的结局。

研究设计与样本

  • 方法学综述,检索已发表文献和国际临床试验注册库,纳入评估血管舒缩症状或泌尿生殖症状治疗的随机对照试验。

主要发现

  • 结局报告与COMMA COS的一致性为中等,且在COS发表后有所增加。
  • 症状所致痛苦、困扰或干扰的历史报告率为2%,而注册临床试验中为62%。
  • MHT和阴道雌激素未被评估所有核心结局,治疗满意度和排尿困难仅9%的研究报告。

关键数值与推荐

  • 历史随机试验中报告症状困扰类结局的比例为2%。
  • 注册临床试验中报告症状困扰类结局的比例为62%。
  • 治疗满意度和排尿困难在仅9%的研究中报告。

临床怎么用

  • 临床解读绝经治疗证据时需注意核心结局报告不全,患者体验类结局常缺失。
  • 未来研究和证据应用应优先关注反映患者生活体验的结局指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Assess uptake of the Core Outcomes in Menopause (COMMA) core outcome sets (COS) and examine whether frontline treatments for vasomotor and genitourinary symptoms have been evaluated against these key outcomes. DESIGN: Methodological review. SETTING: Published literature and international clinical trial registries. POPULATION OR SAMPLE: Randomised controlled trials evaluating treatments for vasomotor symptoms or genitourinary symptoms. METHODS: We explored COS uptake in three ways. First, we reviewed outcome reporting in historical randomised trials. Second, we examined recently registered trials to see whether the COS are being adopted. Finally, we consider how frontline treatments-menopause hormone therapy (MHT) for VMS and vaginal oestrogen for genitourinary symptoms-have been evaluated against these COS. MAIN OUTCOME MEASURES: Proportion of trial outcomes aligned with the COMMA COS. RESULTS: Overall, alignment of outcome reporting against the COS was moderate and has increased after publication of the COS. While reporting of the distress, bother or interference caused by these symptoms has historically been rare (2% of trials), 62% of registered clinical trials capture this outcome. Common treatments for VMS and genitourinary symptoms, MHT and vaginal oestrogen, have not been evaluated for all core outcomes, with treatment satisfaction and dysuria reported in only 9% of studies. CONCLUSION: Despite strong endorsement and improvement in capture of symptom experience and impact, uptake of the full COMMA COS is limited. We call on the menopause research community to prioritise reporting of these outcomes that reflect people's lived experience, so that future evidence is more meaningful, comparable and patient-centred.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Gan J, Steeper M, Hillard T, et al. Modern Management of the Menopause: Are We Measuring What Matters? BJOG. 2026. PMID: 41656930. doi:10.1111/1471-0528.70175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。